Therapy Detail

Therapy Name Trebananib
Therapy Description

Trebananib inhibits angiogenesis through binding to the angiopoietins Ang1 and Ang2, thereby preventing interaction with their receptors (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Trebananib AMG 386 Trebananib inhibits angiogenesis through binding to the angiopoietins Ang1 and Ang2, thereby preventing interaction with their receptors (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Trebananib Phase I Actionable In a Phase I trial, treatment with Trebananib demonstrated tolerability in pediatric patients with advanced solid tumors, and resulted in stable disease for greater than 4 months in one patient with neuroblastoma and one patient with anaplastic astrocytoma (PMID: 28751444). 28751444
Clinical Trial Phase Therapies Title Recruitment Status
NCT01042379 Phase II Trebananib Pertuzumab + Trastuzumab Ganitumab Paclitaxel + Doxorubicin + Cyclophosphamide MK2206 + Trastuzumab Trebananib + Trastuzumab T-DM1 + Pertuzumab I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Recruiting
NCT01493505 Phase III Carboplatin Paclitaxel Trebananib TRINOVA-3 Terminated
NCT01290263 Phase Ib/II Trebananib + Bevacizumab Trebananib Amgen 386 for Recurrent Glioblastoma Completed
NCT01553188 Phase II Prednisone Abiraterone Trebananib AMG 386 and Abiraterone for Advanced Prostate Cancer Completed
NCT01664182 Phase II Trebananib + Sunitinib Trebananib + Pazopanib Trebananib + Sorafenib Trebananib Trebananib + Bevacizumab Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Active, not recruiting